Related Experiment Video
Updated: Mar 23, 2026
08:14
Modeling Stroke in Mice: Permanent Coagulation of the Distal Middle Cerebral Artery
Published on: July 31, 2014
38.8K
The VWF-GPIb axis in ischaemic stroke: lessons from animal models
Frederik Denorme, Simon F De Meyer1
1Simon De Meyer, Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, E. Sabbelaan 53, 8500 Kortrijk, Belgium, Tel.: +32 56 246232, Fax: +32 56 246997,
Thrombosis and Haemostasis
|April 1, 2016
Summary
Targeting the von Willebrand factor (VWF) and platelet glycoprotein Ib (GPIb) interaction shows promise for treating ischemic stroke. Inhibiting this pathway may improve reperfusion and reduce brain damage.
Area of Science:
- Neurology
- Hematology
- Vascular Biology
Background:
- Ischemic stroke, caused by blood clots obstructing cerebral blood flow, is a major cause of death and disability.
- Current reperfusion therapies like tissue plasminogen activator and endovascular thrombectomy have limitations in patient eligibility and can cause reperfusion injury.
- Understanding stroke pathophysiology is crucial for developing improved therapeutic strategies.
Purpose of the Study:
- To review the experimental evidence highlighting the critical role of the von Willebrand factor (VWF)-platelet glycoprotein Ib (GPIb) axis in ischemic stroke.
- To explore the therapeutic potential of targeting the VWF-GPIb interaction for stroke treatment.
Main Methods:
- Review of preclinical and clinical studies investigating the VWF-GPIb interaction in the context of ischemic stroke.
- Analysis of experimental data demonstrating the effects of VWF-GPIb inhibition on thrombolysis and reperfusion injury.
Main Results:
- Clinical and experimental studies increasingly recognize the pathophysiological significance of VWF in ischemic stroke.
- Inhibition of the VWF-GPIb binding interaction demonstrates potential for pro-thrombolytic activity.
- Targeting VWF-GPIb may enhance cerebral reperfusion rates and mitigate ischemic/reperfusion damage.
Conclusions:
- The VWF-GPIb axis is a key player in ischemic stroke pathophysiology.
- Inhibiting the VWF-GPIb interaction represents a promising therapeutic target for improving stroke outcomes.
- Further research into VWF-GPIb targeted therapies could lead to novel treatments for ischemic stroke.
